Nadège Bercovici

Dr. Nadège Bercovici


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PLPierre-Louis Loyher
Pierre-Louis Loyher
PHPauline Hamon
Pauline Hamon
MLMarie Laviron
Marie Laviron
AMAïda Meghraoui-Kheddar
Aïda Meghraoui-Kheddar
EGElena Goncalves
Elena Goncalves
ABAlexandre Boissonnas
Alexandre Boissonnas
Tissue-resident macrophages can self-maintain without contribution of adult hematopoiesis. Herein we show that tissue-resident interstitial macrophages (Res-TAMs) in mouse lungs contribute to the pool of tumor-associated macrophages (TAMs) together with CCR2-dependent recruited macrophages (MoD-TAMs). Res-TAMs largely correlated with tumor cell growth in vivo, while MoD-TAMs accumulation was associated with enhanced tumor spreading. Both cell subsets were depleted after chemotherapy, but MoD-TAMs rapidly recovered and performed phagocytosis-mediated tumor clearance. Interestingly, anti-VEGF treatment combined with chemotherapy inhibited both Res and Mod-TAM reconstitution without affecting monocyte infiltration and improved its efficacy. Our results reveal that the developmental origin of TAMs dictates their relative distribution, function, and response to cancer therapies in lung tumors.

28 January 2020 in eLife
Verified
Journal Article
Open access
MGMarion V Guerin
Marion V Guerin
VFVeronica Finisguerra
Veronica Finisguerra
BEBenoît Van Den Eynde
Benoît Van Den Eynde
NBNadège Bercovici
Nadège Bercovici
ATAlain Trautmann
Alain Trautmann
The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine tumor models often do not work in clinics. In a detailed comparison of transplanted and spontaneous tumor models, we focus on structure–function relationships in the tumor microenvironment. For instance, the architecture of the vascular tree, which depends on whether tumor cells have gone through epithelial-mesenchymal transition, is determinant for the extension of the spontaneous necrosis, and for the intratumoral localization of the immune infiltrate. Another key point is the model-dependent abundance of TGFβ in the tumor, which controls the variable susceptibility of different tumor models to treatments. Grounded in a historical perspective, this review provides a rationale for checking factors that will be key for the transition between preclinical murine models and clinical applications.

7 July 2017 in OncoImmunology
Verified
Journal Article
Open access
JWJulia M. Weiss
Julia M. Weiss
MGMarion V. Guérin
Marion V. Guérin
FRFabienne Regnier
Fabienne Regnier
GRgilles renault
gilles renault
IGIsabelle Galy-Fauroux
Isabelle Galy-Fauroux
NBNadège Bercovici
Nadège Bercovici
Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a ligand of the STimulator of Interferon Genes, STING. The 2 main events rapidly triggered by DMXAA in transplanted PyMT tumors are 1) the disruption of the tumor vasculature, followed by hypoxia and cell death; 2) the release of chemokines. Both events converged to trigger the recruitment of 2 waves of immune cells: a swift, massive recruitment of neutrophils, followed by a delayed rise in monocytes and CD8 T cells in the tumor mass. Depletion experiments in vivo revealed that myeloid cell subsets and T cells need to cooperate to achieve full-blown recruitment and activation at the tumor site and to induce effective secondary cell death leading to tumor regression (Illustration 1). Altogether, our study highlights that the tumor regression induced by the STING agonist DMXAA results from a cascade of events, with an initial vessel destruction followed by several infiltration waves of immune cells which have to cooperate to amplify and sustain the initial effect. We thus provide the first global and detailed kinetic analysis of the anti-tumoral effect of DMXAA and of its different articulated steps.

11 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLuca Simula
Luca Simula
MFMattia Fumagalli
Mattia Fumagalli
LVLene Vimeux
Lene Vimeux
IRIrena Rajnpreht
Irena Rajnpreht
PIPhilippe Icard
Philippe Icard
EDEmmanuel Donnadieu
Emmanuel Donnadieu
The ability of CD8+ T cells to infiltrate solid tumors and reach cancer cells is associated with improved patient survival and responses to immunotherapy. Thus, identifying the factors controlling T cell migration in tumors is critical, so that strategies to intervene on these targets can be developed. Although interstitial motility is a highly energy-demanding process, the metabolic requirements of CD8+ T cells migrating in a 3D environment remain unclear. Here, we demonstrate that the tricarboxylic acid (TCA) cycle is the main metabolic pathway sustaining human CD8+ T cell motility in 3D collagen gels and tumor slices while glycolysis plays a more minor role. Using pharmacological and genetic approaches, we report that CD8+ T cell migration depends on the mitochondrial oxidation of glucose and glutamine, but not fatty acids, and both ATP and ROS produced by mitochondria are required for T cells to migrate. Pharmacological interventions to increase mitochondrial activity improve CD8+ T cell intratumoral migration and CAR T cell recruitment into tumor islets leading to better control of tumor growth in human xenograft models. Our study highlights the rationale of targeting mitochondrial metabolism to enhance the migration and antitumor efficacy of CAR T cells in treating solid tumors.

1 June 2011 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MCMaxime Chapon
Maxime Chapon
CRClotilde Randriamampita
Clotilde Randriamampita
EMEve Maubec
Eve Maubec
CBCécile Badoual
Cécile Badoual
SFStéphane Fouquet
Stéphane Fouquet
NBNadège Bercovici
Nadège Bercovici

7 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWShu-Fang Wang
Shu-Fang Wang
SFStéphane Fouquet
Stéphane Fouquet
MCMaxime Chapon
Maxime Chapon
HSHélène Salmon
Hélène Salmon
FRFabienne Regnier
Fabienne Regnier
NBNadège Bercovici
Nadège Bercovici
To improve cancer immunotherapy, a better understanding of the weak efficiency of tumor-infiltrating T lymphocytes (TIL) is necessary. We have analyzed the functional state of human TIL immediately after resection of three types of tumors (NSCLC, melanoma and RCC). Several signalling pathways (calcium, phosphorylation of ERK and Akt) and cytokine secretion are affected to different extents in TIL, and show a partial spontaneous recovery within a few hours in culture. The global result is an anergy that is quite distinct from clonal anergy induced in vitro, and closer to adaptive tolerance in mice. PD-1 (programmed death -1) is systematically expressed by TIL and may contribute to their anergy by its mere expression, and not only when it interacts with its ligands PD-L1 or PD-L2, which are not expressed by every tumor. Indeed, the TCR-induced calcium and ERK responses were reduced in peripheral blood T cells transfected with PD-1. Inhibition by sodium stibogluconate of the SHP-1 and SHP-2 phosphatases that associate with several inhibitory receptors including PD-1, relieves part of the anergy apparent in TIL or in PD-1-transfected T cells. This work highlights some of the molecular modifications contributing to functional defects of human TIL.